What Astromech does

Astromech is a private AI company founded in 2025 and headquartered in Austin, Texas (Delaware-incorporated as Astromech AI Corp.), operating as a wholly-owned subsidiary of Colossal Biosciences. The company is building the "Large Life Model" — an autonomous biological intelligence system purpose-built to decode the regulatory and evolutionary logic of biology, in contrast to general-purpose large language models. The architecture is designed to operate across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer that supports therapeutic development, trait optimization, programmable biology, and synthetic design. Target users are life sciences and biotech researchers working on understanding and shaping biological systems, with pain points centered on the lack of AI systems capable of multi-species analysis, ancestral reconstruction, and causal evolutionary reasoning.

The technical platform comprises five specialized components: the Pilot's Heuristic Processor (attention-based deep learner for multi-species transcriptomes), the Astrogation Buffer (Bayesian Ancestral Reconstruction for evolutionary trajectories), the Multi-socket Docking Bay (graph-based pangenome capturing population-scale structural variants), Tool-Appendage Calibration (Profile HMM alignment across divergent lineages), and the Droid Grid Network (multi-omics integrator in development). The system is described as an "AI Co-Pilot Through Evolutionary Frontiers" and is being designed to execute rather than merely assist. Leadership includes CEO Ben Lamm, Advisor George Church, and CLO Brian Beard, drawing on Colossal's de-extinction research programs (woolly mammoth, dire wolf, dodo, blue buck) as biological context.

Astromech operates in stealth with no publicly disclosed pricing, no commercial product storefront, and no named customer logos. Approximately $40 million has been raised through a 2025 $30M seed round and a March 2026 SEC Form D filing for $10,499,999, reaching a $2 billion+ unicorn valuation within nine months of founding. Go-to-market is relationship-driven, targeting research institutions and biotech companies through early-access newsletter signup and direct outreach, with an extensive job directory signaling aggressive technical talent acquisition.

Name

Astromech

Legal name

Astromech AI Corp.

Website

https://astromech.com

Company type

Private

Founded year

2025

Operating status

Operating

Short description

Astromech, a Colossal Biosciences subsidiary, develops the Large Life Model — a proprietary AI system purpose-built to decode biological regulation and evolutionary logic across multi-species data for life sciences and biotech researchers.

Ownership category

akta.pro rank

Product category

Bioinformatics AI Platform

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Biological AI systems
• Genomic AI platform
• Synthetic biology tools
• Multi-omics analysis
• Evolutionary reconstruction AI

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels1 record

Marketing channels2 records

Core offering

Astromech develops an AI platform called the Large Life Model, purpose-built to decode the regulatory and evolutionary logic of biology. The system operates across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer. It supports therapeutic development, trait optimization, programmable biology, genomic reasoning, synthesis design, and evolutionary reconstruction for life sciences and biotech research organizations.

Product overview

Astromech is an AI company founded as a subsidiary of Colossal Biosciences, developing a unified biological intelligence platform centered on the Large Life Model. This core AI system is complemented by five specialized technical components: the Pilot's Heuristic Processor (attention-based deep learning across transcriptomes), Astrogation Buffer (Bayesian ancestral reconstruction), Multi-socket Docking Bay (graph-based pangenome analysis), Tool-Appendage Calibration (Profile HMM alignment), and the Droid Grid Network (multi-omics integration). The platform is designed as an autonomous biological intelligence system that enables researchers to navigate, analyze, and predict biological processes at scale.

Differentiator

Problem solved

Functional benefit

Brands

• Large Life Model: A developing AI system purpose-built to decode the regulatory and evolutionary logic of biology. It operates across multi-species inputs and transcriptomic data, incorporating ancestral reconstruction to form a continuously updating biological intelligence layer.

Products and services

• Large Life Model An AI system purpose-built to decode the regulatory and evolutionary logic of biology. Operates across multi-species inputs and transcriptomic data with ancestral reconstruction capabilities, enabling high-resolution insights for therapeutic development, trait optimization, and programmable biology. Targeted at life sciences researchers and biotech organizations.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

One partnership is on record.

• Colossal BiosciencescoreStrategic or Co-development PartnerAstromech was launched as an AI-focused subsidiary of Colossal Biosciences, a Texas-based biotech company founded by Ben Lamm. Colossal's work on de-extinction (woolly mammoth, dire wolf, dodo, Blue Buck) provides the biological research context for Astromech's Large Life Model development. The companies share founding leadership including Ben Lamm as CEO and George Church as Advisor.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology. Comparable in target customer (pharma/biotech research) and value proposition (predictive biology from large-scale data).
• Cradle Bio: AI platform for protein engineering and design, serving biotech customers with generative biology tooling. Comparable in horizontal life-science R&D application and AI-driven design value proposition.
• Recursion Pharmaceuticals: Publicly traded AI drug discovery company using high-dimensional biology and foundation models. Direct competitor in the AI-for-therapeutic-development category, with a mature pipeline and pharma partnerships Astromech lacks.
• Deep Genomics: AI/ML platform for genetic medicine discovery. Comparable in applying AI to RNA biology and therapeutic target identification, with overlapping customer base in pharma R&D.
• Generate Biomedicines: Generative biology platform creating novel protein therapeutics using AI. Comparable in applying foundation-model-class architectures to programmable biology and therapeutic design.
• Isomorphic Labs: Alphabet/DeepMind-backed AI drug discovery company building foundation models for biology. Directly comparable to Astromech's stated mission of purpose-built AI architecture for biological reasoning, with substantially greater capital and compute resources.
• EvolutionaryScale: AI foundation models for biology founded by former Meta AI researchers. Direct overlap with Astromech's Large Life Model concept and recently funded at unicorn-tier valuations, representing near-term competitive threat.

Broad incumbents

• Benchling: Cloud-based R&D platform for life sciences (LIMS/ELN) used across pharma and biotech. Comparable as adjacent life-science informatics infrastructure serving similar research customers.
• Ginkgo Bioworks: Large, publicly traded synthetic biology platform serving ag, industrial, and pharma customers. Comparable in synthetic biology positioning and horizontal life-science platform scope, though much broader and less AI-native.

Emerging players

• Owkin: AI platform combining multi-omics and multimodal data for biomedical research. Comparable in applying AI to multi-omics data integration and predictive biology in pharma/biotech research settings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astromech